HUMA Humacyte, Inc.
Humacyte, Inc. (HUMA) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $41.1K.
Where they traded
Last open-market purchase: September 14, 2026 , by Jones Keith Anthony .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Jones Keith Anthony | Director | Buy | 10,000 | $0.56 | $5.6K | 50,000 | |
| Jones Keith Anthony | Director | Buy | 10,000 | $0.69 | $6.9K | 40,000 | |
| Jones Keith Anthony | Director | Buy | 30,000 | $0.59 | $17.8K | 30,000 | |
| Sebelius Kathleen | Director | Buy | 56,818 | $0.88 | $50.0K | 148,025 | |
| Sander Dale A. | CFO and Chief Corp. Dev. Off | Sell 10b5-1 | 45,887 | $0.90 | $41.1K | 267,213 −14.7% of holding | |
| Parikh Shamik J | Chief Medical Officer | Sell 10b5-1 | 45,887 | $0.90 | $41.1K | 272,713 −14.4% of holding | |
| Constantino Michael T. | Director | Buy | 11,000 | $0.89 | $9.8K | 43,950 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.